Suven Pharmaceuticals Limited Total Liabilities

Latest as of March 2025: Rs11.91 Billion INR ≈ $128.81 Million USD

Suven Pharmaceuticals Limited total liabilities. Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has total liabilities worth Rs11.91 Billion INR (≈ $128.81 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Suven Pharmaceuticals Limited liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Suven Pharmaceuticals Limited (2019–2025)

Total liabilities of Suven Pharmaceuticals Limited from 2019 to 2025. This chart illustrates how Suven Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data.

Suven Pharmaceuticals Limited Competitors by Total Liabilities

The table below lists competitors of Suven Pharmaceuticals Limited ranked by their total liabilities.

Company Country Total Liabilities
Texas Capital Bancshares, Inc.
NASDAQ:TCBI
USA $29.88 Billion
Silgan Holdings Inc
NYSE:SLGN
USA $7.22 Billion
Next Vision Stabilized Systems
TA:NXSN
Israel ILA28.00 Million
KONINKLIJKE VOP.UNSP.ADR
F:VPK
Germany €3.54 Billion
Novanta Inc
F:1GSN
Germany €704.34 Million
Kilroy Realty Corp
NYSE:KRC
USA $5.18 Billion
Union Bank of Taiwan Pref
TW:2838A
Taiwan NT$980.49 Billion
Mega Or
TA:MGOR
Israel ILA7.50 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down Suven Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Suven Pharmaceuticals Limited.

Liquidity & Leverage Metrics

Suven Pharmaceuticals Limited Total Liabilities Ratios Explained

Suven Pharmaceuticals Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.43 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.70 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.39 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suven Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suven Pharmaceuticals Limited (2019–2025)

The table below shows the annual total liabilities of Suven Pharmaceuticals Limited from 2019 to 2025.

Year Total Liabilities Change
2025-03-31 Rs11.91 Billion
≈ $128.81 Million
+485.53%
2024-03-31 Rs2.03 Billion
≈ $22.00 Million
-11.77%
2023-03-31 Rs2.31 Billion
≈ $24.93 Million
-23.76%
2022-03-31 Rs3.02 Billion
≈ $32.70 Million
+2.98%
2021-03-31 Rs2.94 Billion
≈ $31.76 Million
-10.48%
2020-03-31 Rs3.28 Billion
≈ $35.48 Million
+70.21%
2019-03-31 Rs1.93 Billion
≈ $20.84 Million
--

About Suven Pharmaceuticals Limited

NSE:SUVENPHAR India Drug Manufacturers - Specialty & Generic
Market Cap
$4.40 Billion
Rs406.97 Billion INR
Market Cap Rank
#3786 Global
#171 in India
Share Price
Rs1063.80
Change (1 day)
+0.00%
52-Week Range
Rs1063.80 - Rs1063.80
All Time High
Rs1334.20
About

Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more